RAS testing for colorectal cancer patients is reliable in European laboratories that pass external quality assessment by Tack, V. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/191936
 
 
 
Please be advised that this information was generated on 2019-06-01 and may be subject to
change.
Article 25fa pilot End User Agreement 
This publication is distributed under the terms of Article 25fa of the Dutch Copyright Act (Auteurswet) 
with explicit consent by the author. Dutch law entitles the maker of a short scientific work funded either 
wholly or partially by Dutch public funds to make that work publicly available for no consideration 
following a reasonable period of time after the work was first published, provided that clear reference is 
made to the source of the first publication of the work.  
This publication is distributed under The Association of Universities in the Netherlands (VSNU) ‘Article 
25fa implementation’ pilot project. In this pilot research outputs of researchers employed by Dutch 
Universities that comply with the legal requirements of Article 25fa of the Dutch Copyright Act are 
distributed online and free of cost or other barriers in institutional repositories. Research outputs are 
distributed six months after their first online publication in the original published version and with 
proper attribution to the source of the original publication.  
You are permitted to download and use the publication for personal purposes. All rights remain with the 
author(s) and/or copyrights owner(s) of this work. Any use of the publication other than authorised 
under this licence or copyright law is prohibited. 
If you believe that digital publication of certain material infringes any of your rights or (privacy) 
interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library 
will make the material inaccessible and/or remove it from the website. Please contact the Library 
through email: copyright@ubn.ru.nl, or send a letter to: 
University Library  
Radboud University 
Copyright Information Point 
PO Box 9100 
6500 HA Nijmegen 
 
You will be contacted as soon as possible. 
ORIGINAL ARTICLE
RAS testing for colorectal cancer patients is reliable in European
laboratories that pass external quality assessment
V. Tack1 & M. J. L. Ligtenberg2,3 & A. G. Siebers2 & P. D. M. Rombout2 & P. D. Dabir2,4 & R. D. A. Weren2 &
J. H. J. M. van Krieken2 & E. M. C. Dequeker1
Received: 5 October 2017 /Revised: 11 December 2017 /Accepted: 28 December 2017 /Published online: 15 January 2018
# Springer-Verlag GmbH Germany, part of Springer Nature 2018
Abstract
Wild-type status ofKRAS and the NRAS gene (exon 2, 3, and 4) in the tumor should be determined before treatment of metastatic
colorectal cancer (mCRC) patients with EGFR-targeting agents. There is a large variation in test methods to determine RAS
status, and more sensitive detection methods were recently introduced. Data from quality assessment programs indicate substan-
tial error rates. This study assessed the completeness and correctness of RAS testing in European laboratories that successfully
passed external quality assessment (EQA). Participants were requested to send material of their most recent ten patients with
mCRC who had been tested for RAS status. Isolated DNA, a hematoxylin and eosin stained tissue slide with a marked area for
macrodissection and accompanying patient reports were requested. Samples were reevaluated in a reference laboratory by using a
next-generation sequencing approach. In total, 31 laboratories sent in the requested material (n = 309). Despite regulations for
anti-EGFR therapy, one institute did not perform full RAS testing. Reanalysis was possible for 274 samples with sufficient DNA
available. In the hotspot codons of KRAS and NRAS, seven discordant results were obtained in total, five of them leading to a
different prediction of anti-EGFR therapy efficacy (2%; n = 274). Results show that oncologists can rely on the quality of
laboratories with good performance in EQA. Oncologists need to be aware that the testing laboratory participates successfully
in EQA programs. Some EQA providers list the good performing laboratories on their website.
Keywords Reproducibility . Quality assurance .Molecular pathology . Biological markers . Colorectal neoplasms
Introduction
Today, variants in the KRAS and the NRAS genes (exon 2,
3, and 4) are considered to be important biomarkers for
anti-EGFR therapy decisions for patients with metastatic
colorectal cancer (mCRC). Targeted anti-EGFR agents,
such as panitumumab and cetuximab, are indicated only
for patients with a wild-type RAS tumor [1, 2]. Pathology
laboratories perform KRAS variant analysis since 2008,
when it became mandatory to confirm the wild-type status
of KRAS exon 2 before anti-EGFR treatment is prescribed
[3]. The outcome of phase III trials (PRIME and FIRE) in
2013 resulted in addition of the mutational status of NRAS
and extra exons of KRAS as predictive biomarkers for
anti-EGFR therapy decisions [4].
Another important biomarker is a somatic activating vari-
ant affecting the BRAF gene. This is a well-known negative
prognostic marker in mCRC, but testing is not mandatory
prior to anti-EGFR therapy decisions. Even though many lab-
oratories include BRAF in their testing strategy for anti-EGFR
This article is part of the Topical Collection on Quality in Pathology
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therapy, there is no consensus about the specific effect of
activating variants in BRAF on this therapy [5, 6].
Shortly after publication of the more stringent rules for
panitumumab and cetuximab usage, results of external quality
assessments (EQAs) showed concerning results [7–9]. Full
RAS testing (defined as codons 12, 13, 59, 61, 117, and 146
of KRAS and NRAS) was only implemented by half of the
laboratories participating in the European Society of
Pathology (ESP) program, and there were numerous errors
in testing the new gene segments. False positive and false
negative results can have detrimental consequences for the
patient’s treatment and must be avoided at all times [10].
There is a large variation in the testing methods used to
determine the RAS and BRAF status and more sensitive detec-
tion methods were introduced in routine testing [11]. There is
a risk of reporting false negative or false positive results due to
different sensitivities of methods, lack of experience in the
laboratory, and other, partly unknown, factors. In the
Netherlands, where few laboratories fail EQA programs, the
result of retesting routine samples was reassuring [12].
In this study, the completeness and correctness of RAS test-
ing (KRAS and NRAS exons 2, 3, and 4) was assessed in a
subset of European laboratories, from 17 different countries,
that successfully participated in previous EQA schemes.
Materials and methods
All European laboratories that were successful in at least one
of their two last ESP Colon EQA scheme participations [13],
with a known accreditation status that did not change in the
last 3 years, were invited to participate in this study (n = 126).
From 50 candidature forms, a final selection of 42 laboratories
was made depending on the most recent participation in the
ESP Colon EQA scheme.
Participating laboratories were requested the following ma-
terial of themost recent ten patients tested forRAS variant status
(January–September 2016): a hematoxylin and eosin (H&E)
slide marked with the area used for macrodissection and
DNA isolation, 50 μl DNA (10 ng/μl) to accommodate auto-
matic processing in the reference laboratory, and the original
test reports. The participants received a survey regarding the
testing strategy and the techniques used to analyze the samples.
The DNA samples received from the participating labora-
tories were retested in the Department of Pathology at
Radboudumc, Nijmegen, the Netherlands. This laboratory is
accredited according to ISO 15189 for their NGS activities
and will be further referred to as Bthe reference laboratory .^
The anonymized original reports were received and analyzed
in the Biomedical Quality Assurance Research Unit of the KU
Leuven (Belgium). Any discordant result between the partic-
ipant’s result and the reference laboratory was repeated in the
reference laboratory.
The histological slides were reviewed individually for neo-
plastic cell percentage by two pathologists who used a recently
developed algorithm, which was finalized by a consensus to a
single value. Quantification of the DNA in the samples was
done using the dsDNAbroad range kit on theQubit 3.0 platform
(Thermo Fisher Scientific). DNA samples with a measurable
amount of DNA (n = 294) were analyzed in duplicate using a
Cancer Hotspot panel based on single-molecule molecular in-
version probes (smMIPs) [14]. Analysis was donewith SeqNext
software v.4.1.2. (JSI medical systems GmbH). Only codons 4–
23, 42–71, 98–119, and 135–150 of the KRAS gene
(NM_004985.4), codons 1–21, 55–81, and 105–150 of the
NRAS gene (NM_002524.4), and codons 582–615 of the
BRAF gene (NM_004333.4) were included in the data analysis.
For variant calling a threshold of 11 unique reads and 3 variant
reads was applied. Due to the high level of formalin-fixed par-
affin-embedded artifacts in some samples, the cutoff for the
variant allele frequency was set at ≥ 5%. This data analysis
was slightly different from the routine strategy, where a cutoff
of 1% is used. Themean amount of unique reads varied between
530 (KRAS codon 61) and 1553 (BRAF codon 594–601) (for
details, see Supplementary Table 2). The data of any discrepant
result were reanalyzed in detail, according to the routine proce-
dures. The evaluation was blinded for original test results.
Results from the reference laboratory were compared with
results in the original patient reports of the participating labo-
ratories. Information such as sensitivity and neoplastic cell
percentage were also available from these reports.
Statistical analysis was done with IBM SPSS statistics ver-
sion 22. Comparison of means was done with a t test.
Results
From the 42 selected laboratories for this study, 31 labora-
tories sent in their DNA samples along with respective
patient reports. One laboratory did not fill in the requested
survey, and for one laboratory, only nine samples were
received. A total of 309 samples were received, of which
274 gave reliable results after reanalysis by the reference
laboratory. The participants belonged to 17 different coun-
tries. More detailed information on the countries and char-
acteristics can be found in Table 1. The majority of the
participants (61%) had a university (hospital) and research
background, 36% was a laboratory in a public or a private
hospital, and 3% were private laboratories. Only 61% of
the institutes was accredited according to an international
standard (ISO 15189) or a national equivalent [15–17].
The neoplastic cell percentage on the HE slides was
reassessed by two pathologists for 270 samples of which the
H&E slides were available and ranged between 10 and 90%
after consensus. Themajority of the samples had an estimation
between 30 and 70%. The percentage of neoplastic cells was
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assessed in total by three different pathologists, two from the
reference laboratory and one from the participating laboratory.
Paired statistical analysis of these assessments, excluding
cases where a range is given instead of an exact percentage
of neoplastic cells, showed no significant differences between
the original estimate and the consensus estimate in the refer-
ence laboratory (p = 0.817, n = 195). Analyses on the neo-
plastic cell content were performed using the pathology esti-
mations of the reference laboratory.
Even though confirmation of the wild-type status of NRAS
and KRAS (codons 12, 13, 59, 61, 117, 146) is mandatory
before anti-EGFR therapy, one institute did not perform full
RAS testing. They did not include codon 59 of the KRAS gene.
Themajority of the laboratories (84%, n = 31) performedBRAF
variant analysis for one or more of the samples. However, 13 of
these 26 participants did not perform BRAF testing on all the
samples. For one laboratory, none of the BRAF-tested samples
could be reanalyzed by the reference laboratory and these were
therefore not taken into account for further analysis.
The use of NGS-based methods and non-NGS commercial
kits is similar for variant analysis of the KRAS gene, 38% and
39%, respectively. ForNRAS and BRAF variant analysis, NGS
(42% and 55% respectively) is more popular than commercial
non-NGS kits (34 and 19%, respectively). Laboratory-
developed tests (non-NGS) were used by a quarter of the
participants for KRAS, NRAS, and BRAF variant analysis
(20%, 23%, and 26%, respectively). One laboratory (3%) used
a combination of a commercial non-NGS kit with Sanger se-
quencing for KRAS variant analysis.
The concordance between the genotype reported by the par-
ticipating and reference laboratories is presented in Table 2.
Taken into account the tested regions and the samples for which
the reanalysis by the reference laboratory gave reliable results,
24 laboratories (77%)were able to correctly type all samples. Of
these, four laboratories sent in samples that contained a BRAF
variant that was identified by the reference laboratory, but was
not included in the tested region of that particular laboratory.
There were seven discordant genotypes at clinically rele-
vant positions: four false negatives, one false positive, one
insertion-deletion instead of a single nucleotide substitution,
and one sample with a second KRASmutation. Not more than
one genotyping error was made by each laboratory. Table 3
gives a more detailed information on these variants, which all
involved a KRAS variant. One of the variants that was missed
was due to the limit of detection of the laboratory’s method,
which was 10% while the missed variant was present at a
frequency of 6%. The percentage of tumor cells in this sample
was 70%. All seven laboratories with genotyping errors had a
university (hospital) and research background and four of
them were accredited. The average neoplastic cell content of
these seven mistyped samples was 47%, with five of the seven
samples above 40%. The percentage of neoplastic cells was
known for 233 of the 267 concordant samples. The average
neoplastic cell content of the samples that were correctly typed
was 52%. The two groups, samples with discordant results
and those without do not significantly differ from each other
regarding neoplastic cell content (p = 0.535). In total six
BRAF p.(V600E) variants and two variants in codon 594 of
BRAF were missed by the participants as they were not in-
cluded in their test regimen. Moreover, seven variants at po-
sitions without known clinical relevance were identified
(Table 2).
In Table 4, an overview is shown for the frequency of the
variants in each relevant codon of KRAS, NRAS, and BRAF as
determined in the reference laboratory (n = 274). Details on
all specific variants can be found in Supplemental Table 1.
Discussion
The aim of this study was to assess quality of routine RAS
testing in Europe, by verifying its reproducibility. In addition,
implementation of completeKRAS and NRAS (exons 2, 3, and
4) testing in diagnostic setting was evaluated.
Overall, a very good concordance was observed between
the participating laboratories and the reference laboratory
(97%). For five patients (2%), the reference laboratory generated
a genotype that leads to a different anti-EGFR therapy advice.
In two patients (1%), the anti-EGFR therapy advice remained
the same. In case the four patients with a false negative result
actually received anti-EGFR therapy, this could have had ad-
verse effects instead of improvement of progression-free sur-
vival [4]. The participants with discordant results all used
different methods (Table 3). Laboratories using NGS technol-
ogies made no mistakes which lead to false negative or false
positive results for therapy decisions. This observation may be
due to the higher familiarity with genotyping technologies.
A limitation of our study is that not all laboratories had
sufficient residual DNA that could be evaluated in the au-
tomatic workflow of the reference laboratory. This may
have caused a selection bias towards samples with large
tumor areas and laboratories that isolated a surplus of
DNA in their routine workflow. Actually, six participants
indicated that the requested DNA amount was higher than
what was extracted in their routine practice. This did not
seem to cause much problems, as only for eight samples of
these participants the repeat NGS analysis gave low cov-
erage. On the other hand, the amount of DNA supplied by
some of the participating laboratories was so low that the
concentration could not be measured by Qubit analysis.
The frequency of the variants in the mCRC samples used in
this study (Table 4 and Supplemental Table 1) is in accordance
with previously reported results [4, 12, 18–20]. KRAS exon 2
variants were most commonly identified (41%) and no NRAS
exon 4 variants occurred. BRAF variants were present in 10%
of the samples, of which BRAF c.1799T>A p.(Val600Glu)
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was most frequent. One exception to the literature is the par-
allel occurrence of both BRAF and RAS variants (one sample
with KRAS c.436G>A p.(Ala146Thr) and BRAF c.1780G>A
p.(Asp594Asn), and one sample with NRAS c.35G>A
p.(Gly12Asp), and BRAF c.1780G>A p.(Asp594Gly)). In
both samples, this concerned a variant of BRAF codon 594
that causes inactivation rather than activation of BRAF. In
contrast to BRAF codon 600 variants, which are considered
mutually exclusive with RAS variants, BRAF codon 594 var-
iants co-occur relatively frequently with RAS variants [21].
This study shows that successful participation in EQA,
reflects complete and correct reporting of results for RAS test-
ing in routine analysis. Despite the label given by EMA to
EGFR-targeted agents for patients with mCRC, one laborato-
ry did not test all relevant codons (12, 13, 59, 61, 117, 146)
and did not mention this limitation in the reports. This is an
improvement compared to studies performed right after the
labels changed [7, 12, 20].
Because of the potential negative consequences follow-
ing a false negative result, laboratories should be careful
when reporting a wild-type sample in case of incomplete
RAS testing. Also, laboratories using less sensitive
methods, such as Sanger sequencing, without mentioning
the sensitivity of the method in the report are at risk of
reporting false negative results. The tested regions and lim-
itations of the test should be clearly mentioned in the
methods section of the patient report and further testing
should be recommended for the complete RAS gene [22].
In addition, the tumor cell content is an important elementTa
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Table 4 Overview of the variants in the samples, as determined by the
NGS panel of the reference laboratory in Nijmegen. Samples without a
reliable result (n = 35) were not taken into account
Variant in sample Number of samples (%) n = 274 Agreement (%)
KRAS 134 (49%) 127/134 (95%)
Codon 12 90 (33%)a 87/90 (97%)
Codon 13 23 (8%) 21/23 (91%)
Codon 59 1 (0%) 1/1 (100%)
Codon 61 8 (3%) 7/8 (88%)
Codon 146 12 (4%)b 11/12 (92%)
NRAS 15 (5%) 15/15 (100%)
Codon 12 4 (1%)b 4/4 (100%)
Codon 13 2 (1%) 2/2 (100%)
Codon 61 9 (3%) 9/9 (100%)
BRAF 28 (10%) 28/28 (100%)
Codon 600 24 (9%) 24/24 (100%)
Codon 594 4 (1%)b 4/4 (100%)
Wild-type 99 (36%) 99/99 (100%)
a Two codon 12 variants in one sample
b Two samples contained both a RAS variant and a BRAF variant
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on the report to allow an unambiguous interpretation of the
result in relation to the used testing method [23].
Different elements were taken into account to provide a
good estimation of the reproducibility of RAS testing. The
selected group of participants had different experience levels
withRAS testing and different settings. Laboratories following
a specific standard and laboratories without accreditation were
also included. The invited participants were good performers
in EQA, which could lead to an overestimation of the general
reproducibility of RAS testing in Europe. Taken this into ac-
count, it could be concluded that a good EQA performance is
indicative of reliable performance in routine practice. Some
EQA providers publish a list of laboratories that passed the
EQA program [24, 25].
Conclusion
The results show that patients and oncologists can rely on the
results of routine RAS testing in pathology laboratories that
successfully participated in EQA in Europe. Nevertheless,
laboratories must acknowledge samples with limited quality
in the diagnostic report. Providing conclusive results of such
samples can result in a wrong therapy decision.
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